• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Ascensia Diabetes Care

Senseonics wins CE mark approval for 180-day Eversense E3 CGM

June 16, 2022 By Sean Whooley

Senseonics Eversense E3 Ascensia Diabetes Care

Senseonics (NYSE:SENS) announced today that it received CE mark for the next-generation Eversense E3 CGM system. Germantown, Maryland-based Senseonics offered a previous-generation continuous glucose monitor (CGM) with a 90-day wear time. Its next-generation Eversense E3 can be used for up to six months (180 days). Europe already had a 180-day Senseonics CGM system available (Eversense […]

Filed Under: Business/Financial News, Diabetes, Drug-Device Combinations, Featured, Patient Monitoring, Regulatory/Compliance, Technology Tagged With: Ascensia Diabetes Care, Senseonics

Senseonics beats The Street in Q1 following Eversense E3 launch

May 11, 2022 By Sean Whooley

Senseonics Eversense E3 Ascensia Diabetes Care

Senseonics (NYSE:SENS) posted first-quarter results that topped the consensus revenue forecast on Wall Street. The Germantown, Maryland-based company posted profits of $86.7 million, or 19¢ per share, on sales of $2.5 million for the three months ended March 31, 2022, for a massive bottom-line gain from losses of $249.5 million this time last year despite […]

Filed Under: Business/Financial News, Diabetes, Drug-Device Combinations, Featured, MassDevice Earnings Roundup, Patient Monitoring, Technology, Wall Street Beat Tagged With: Ascensia Diabetes Care, Senseonics

CGMs, insulin pumps and more: the biggest diabetes news to come out of ATTD 2022

May 3, 2022 By Sean Whooley

ATTD 2022 diabetes tech

All kinds of technologies were on display at the Advanced Technologies & Treatments for Diabetes (ATTD) conference in Barcelona last week. From continuous glucose monitoring (CGM) to automated insulin delivery, with plenty in between, a number of companies shared positive data for their diabetes offerings. Here are five of the biggest stories to come out […]

Filed Under: Auto-injectors, Business/Financial News, Clinical Trials, Diabetes, Drug-Device Combinations, Featured, Patient Monitoring Tagged With: abbott, Ascensia Diabetes Care, Beta Bionics, CamDiab, dariohealth, Dexcom, Diabeloop, Insulet, Medtronic, One Drop, Tandem Diabetes Care, Walmart, welldoc, Ypsomed

Study shows fewer out-of-target blood glucose levels using Ascensia’s monitoring system

May 2, 2022 By Sean Whooley

Ascensia Diabetes

Ascensia Diabetes Care announced today that a new study demonstrates reduced out-of-target blood glucose ranges with its Contour system. The company, which distributes Senseonics’ Eversense continuous glucose monitor (CGM), develops the Contour blood glucose monitoring (BGM) systems and the Contour diabetes app (CDA) for people with diabetes who are managing their blood glucose levels. According […]

Filed Under: Clinical Trials, Diabetes, Drug-Device Combinations, Featured, Patient Monitoring Tagged With: Ascensia Diabetes Care

Senseonics announces first Eversense E3 CGM implant in U.S.

April 7, 2022 By Sean Whooley

Senseonics Eversense E3 Ascensia Diabetes Care

Senseonics (NYSE:SENS) announced today that the first patient was implanted with its next-generation Eversense E3 continuous glucose monitor. Germantown, Maryland-based Senseonics, in partnership with Ascensia Diabetes Care, launched the Eversense E3 long-term implantable CGM system in the U.S. earlier this week. The system received FDA approval in February for use lasting up to six months […]

Filed Under: Business/Financial News, Diabetes, Drug-Device Combinations, Featured, Implants, Patient Monitoring Tagged With: Ascensia Diabetes Care, Eversense, Senseonics

Ascensia launches Senseonics’ next-gen 180-day Eversense E3 CGM in U.S.

April 4, 2022 By Sean Whooley

Senseonics Eversense E3 Ascensia Diabetes Care

Ascensia Diabetes Care announced today that it launched the Senseonics (NYSE:SENS) Eversense E3 system in the U.S. The next-generation Eversense E3 continuous glucose monitoring (CGM) system, developed by Germantown, Maryland-based Senseonics, received FDA approval in February for use lasting up to six months (180 days), making it the longest-lasting CGM sensor available in the U.S. Parsippany, […]

Filed Under: Business/Financial News, Diabetes, Drug-Device Combinations, Featured, Patient Monitoring Tagged With: Ascensia Diabetes Care, Senseonics

9am.health partners with Ascensia to add blood glucose meter to diabetes toolkit

March 23, 2022 By Sean Whooley

9am.health ascensia diabetes care

9am.health announced today that it now offers the Ascensia Diabetes Care Contour Next One and Contour Next products in its diabetes kit. Patients with type 2 diabetes and prediabetes can now add Ascensia’s Contour Next One blood glucose meter and Contour Next glucose test strips to a personalized treatment plan as part of the all-in-one […]

Filed Under: Auto-injectors, Big Data, Business/Financial News, Diabetes, Drug-Device Combinations, Featured, Patient Monitoring Tagged With: 9am.health, Ascensia Diabetes Care

Senseonics wins FDA approval for next-generation Eversense 180-day CGM, provides 2022 outlook

February 11, 2022 By Sean Whooley

Eversense CGM Senseonics

Senseonics (NYSE:SENS) announced today that the FDA approved its next-generation continuous glucose monitor system, which lasts up to half a year. Germantown, Maryland–based Senseonics designed the Eversense E3, which includes proprietary sacrificial boronic acid (SBA) technology, to extend longevity to six months (180 days). Senseonics previously offered the system with a 90-day wear time. Data […]

Filed Under: Business/Financial News, Diabetes, Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Patient Monitoring, Regulatory/Compliance, Wall Street Beat Tagged With: Ascensia Diabetes Care, FDA, Senseonics

Ascensia inks CGM distro, development deal with Poctech

January 8, 2019 By Sarah Faulkner

Ascensia Diabetes

Ascensia Diabetes Care said this week that inked a deal to co-develop and distribute continuous glucose monitoring systems with device developer Poctech. According to the terms of the deal, Ascensia will become the exclusive distributor for Poctech’s existing CGM product in 13 selected markets. Ascensia said it plans to start distributing the device in the […]

Filed Under: Business/Financial News, Diabetes, Featured, mHealth (Mobile Health), Patient Monitoring Tagged With: Ascensia Diabetes Care

Medtronic wins CE Mark for MiniMed 670G hybrid closed-loop insulin system

June 25, 2018 By Brad Perriello

Medtronic MiniMed 670G

Medtronic (NYSE:MDT) said today that it won CE Mark approval in the European Union for its MiniMed 670G hybrid closed-loop insulin management system for Type I diabetes patients age 7 and older. Fridley, Minn.-based Medtronic said it has clinical programs under way to back expanded indications for the device, which is designed to continuously monitor regulate […]

Filed Under: Diabetes, Featured, Regulatory/Compliance Tagged With: Ascensia Diabetes Care, Medtronic

  • Go to page 1
  • Go to page 2
  • Go to Next Page »

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech 100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Souring
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS